Clinical Trials

NCT06872333 | RECRUITING | PHASE2
62 participants

Allo HSCT for High Risk Hemoglobinopathies

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-04
Start Date:
2024-11-19
Completion:
2030-06-01
Conditions
  • Graft Failure
  • Sickle Cell Disease
  • Hemoglobinopathies
Interventions
  • DRUG
  • RADIATION
  • BIOLOGICAL
No Results Yet
NCT06854133 | ACTIVE_NOT_RECRUITING
600 participants

Factors of Effectiveness in Italian Forensic Treatment

Study Type:
OBSERVATIONAL
Last Updated:
2026-06-04
Start Date:
2025-02-01
Completion:
2030-12-31
Conditions
  • Forensic Psychiatric Patients
  • Not Guilty by Reason of Insanity (NGRI)
  • Incompetent to Stand Trial (IST)
  • Psychotic Disorders
  • Community-based Forensic Treatment
  • Violent Behaviour and Recidivism
  • Security Measures (Custodial and Non-custodial
No Results Yet
NCT06831110 | RECRUITING
2000 participants

Aquagenic Wrinkling Prediction

Study Type:
OBSERVATIONAL
Last Updated:
2026-06-04
Start Date:
2025-03-06
Completion:
2026-12-31
Conditions
  • Aquagenic Wrinkling of Palms
  • Carrier State
Interventions
  • PROCEDURE
No Results Yet
NCT06829953 | RECRUITING | NA
75 participants

Get ActivE Study for At-risk Youth

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-04
Start Date:
2025-03-27
Completion:
2026-12-31
Conditions
  • Anhedonia
  • Depression and Suicide Ideation
Interventions
  • BEHAVIORAL
No Results Yet
NCT06792500 | NOT_YET_RECRUITING | PHASE1/PHASE2
24 participants

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-04
Start Date:
2026-10-31
Completion:
2028-03-31
Conditions
  • MELAS Syndrome
  • Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
  • DRUG
No Results Yet
NCT06607692 | RECRUITING | PHASE1/PHASE2
25 participants

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-04
Start Date:
2024-09-20
Completion:
2029-07-31
Conditions
  • Solid Tumor Cancer
  • Medulloblastoma
  • High Risk Neuroblastoma
  • High Grade Gliomas
  • Meningioma
  • Paraganglioma
  • Pheochromocytoma
  • Neuroendocrine Tumours (NET)
  • Adrenal Tumours
  • DIPG
  • Glioblastoma
  • Glioblastoma (GBM)
  • Osteosarcoma Recurrent
  • Carcinoma Adrenal
  • Synovial Sarcomas
  • Esthesioneuroblastoma
  • Neuroblastoma Recurrent
  • Solid Tumor Refractory to Conventional Treatment
  • Medulloblastoma Recurrent
  • Paraganglioma/ Phaeochromocytoma
  • Ependymoma
  • Ependymoma Recurrent
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page